EU GMP Annex 1 Contamination Control Strategy for Sterile Injectables

Contamination Control Challenges in Sterile Manufacturing

Contamination Control Strategy for Sterile Manufacturing

How Can You Build a Contamination Control Strategy (CCS)?

To build a CCS, drug manufacturers are expected to conduct studies to monitor and/or reduce particulate and contaminant levels, assure sterility, and work towards the use of barrier technologies.

Container Closure Integrity Testing

How Do You Effectively Maintain Container Closure Integrity (CCI)?

Maintaining CCI requires understanding of packaging design, component quality, process capability, validated testing, stability confirmation, and lifecycle governance.

Container Closure Integrity Testing

How Do You Manage Extractables and Leachables (E&L) to Meet Regulatory Requirements?

It is an important expectation to document evidence that E&L risks are understood and monitored to ensure product quality and patient safety.

Assessing Components for Contamination Control and Lifecycle Management

1

PRODUCT - Component Specifications

What are your current component quality specifications for particulates, bioburden, and endotoxins? Do they need to be tighter? Consider our premium NovaPure® components with best-in-class levels of quality, performance, and risk mitigation.


2

PROCESS - Manufacturing Design

How will your components and finished drug product be sterilized? How will your components be introduced to the fill/finish line? West’s analytical testing services can support your sterilization process validation.


3

PROTECTION - Container Closure Integrity

Do you fully understand the multiple factors affecting CCI? What monitoring and testing plan is in place over the drug product shelf life to ensure sterility? West provides testing and analysis to help ensure CCI and performance based on robust CCI data.


4

PROOF - Documentation & Service

Does your supplier have a holistic CCS focused on continual improvement? What documentation is available to support your CCS? West's trusted quality reputation positions us to help you meet evolving global regulatory needs.


Learn about Annex 1, CCS and CCI From These Resources
Want to Speak with an Annex 1 Expert?

Partner with West’s cutting-edge primary packaging technologies for your complex drug molecules

NovaPure® - Highest quality components trusted by approved molecules Learn More

 West NovaPure® primary packaging technologies
Mitigate the Risk with Unwanted Stopper Interactions

Mitigate risk as you protect lyo and liquid drugs from visible, subvisible particles and unwanted stopper interactions.

Protect your drug components

Protect your drug with components of superior quality that allow you to choose your preferred/differentiated delivery system.

Optimize syringe performance by reducing plunger variability

Optimize syringe performance by reducing plunger variability and reducing the amount of free silicone oil while maximizing quality.

Learn more about products that can support your EU GMP Annex 1 compliance

Products for EU GMP Annex 1 Compliance

Whether it’s a vial or prefillable syringe, West has packaging components and systems to help ensure your EU GMP Annex 1 compliance

Services for EU GMP Annex 1 Compliance

West has the analytical services and regulatory support to help ensure your products and manufacturing meet
EU GMP Annex 1 regulations and standards

If you would like to speak to a services and solutions specialist
Other West Products to Help You Ensure GMP Annex 1 Compliance

NovaPure and Flip-Off are registered trademarks of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.
Crystal Zenith and D Sigma are trademarks of Daikyo Seiko, Ltd. and are used under license.
Corning and Valor are registered trademarks of Corning Incorporated.
West Pharmaceutical Services, Inc. is the exclusive distributor of Corning® Valor® vials.